Former CEO resigns from Molecular Insight board

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

David S. Barlow has resigned from the board of directors of Molecular Insight Pharmaceuticals, a Cambridge, Mass.-based developer of radiotherapeutics and molecular imaging agents in oncology and cardiology.

The resignation went into effect Dec. 30, 2008 and was related to Barlow’s “disagreements with the board,” he said in a statement.

Barlow is the former CEO of Molecular Insight. In September 2008, the company announced that Barlow would immediately be replaced by interim CEO and chairman of the board John Babich, who formerly served as president and chief scientific officer of Molecular Insight before taking the helm.